Collaborations & Agreements

• Page 4 of 5 (41 items) First 1 2 3 4 5 

• Confusing Choices for Doctors and Type 2 Diabetes Patients
  Drugs in development and on the market are dogged by serious side effects.
• Clinical Trial Failures Further Signal Pancreatic Cancer’s Intractable Nature
  Researchers need to step out of the gemcitabine box and also take on the development of diagnostics for early detection.
• Market Exclusivity—Paramount in Evaluating Target Companies
  The main related factors are relevant facts, freedom to operate, IP, third-party agreements, and regulatory exclusivity.
• Biogen Idec and Facet—Following the Money
  Facet considers Biogen’s $356 million takeover attempt a low-ball offer.
• Chasing the Therapeutic Potential of miRNAs
  The spate of deal-making, new company formations, and patent applications have set up miRNAs as the next wave in nucleic acid-based drugs.
• When Is Revenue Not Revenue for Biotech Firms?
  Proposed changes in accounting rules highlight complexity for public companies.
• Need for Novel Approaches to Treating HIV Still Exists
  As resistance continues to be a problem, firms are trying to exploit characteristics that allow the virus to adapt seemingly endlessly.
• Opinion—Regulatory Planning Key for Emerging Technology Companies
  Strategies formed early help keep investors and partners happy as well as create a smoother development path.
• Genentech Goes Beyond Antibodies with Bayhill Therapeutics Diabetes Deal
  Limitations with using mAbs for chronic diseases, and negative results from line-extension trials with Avastin are possible reasons.
• Biotech Companies Face the Key Question—Deal or No Deal?
  Advice: Set aside dreams of becoming the next Amgen or Genentech; instead know when to partner, take the money, and run.

• Page 4 of 5 (41 items) First 1 2 3 4 5